Biotech News
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused...
Related news
SPROSpero Therapeutics2026-07-27 13:00 EST
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
SPROSpero Therapeutics2026-08-04 21:01 EST
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
ANTXAN2 Therapeutics2026-08-24 11:00 EST
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
COCPCocrystal Pharma2026-06-03 11:00 EST
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
VIRIVirios Therapeutics2026-06-30 12:45 EST
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
ANTXAN2 Therapeutics2026-08-11 20:00 EST
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
OGENOragenics2026-05-07 12:30 EST
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
COCPCocrystal Pharma2026-08-17 15:17 EST
Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors
AVIRAtea2026-08-05 11:00 EST
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
ASMBAssembly Biosciences2026-05-26 20:05 EST
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Spero Therapeutics
Immunology and Inflammation Company Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious immune-mediated diseases. Its internal strategy now centers on CD40 ligand inhibition. SP001 SP001 is a third-generation, Fc-silent monoclonal antibody targeting CD40 ligand. The molecule is designed to...
Recent company news
SPROSpero Therapeutics2026-08-12 21:01 EST
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
SPROSpero Therapeutics2026-08-05 21:05 EST
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SPROSpero Therapeutics2026-08-04 21:01 EST
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
SPROSpero Therapeutics2026-07-27 13:00 EST
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
SPROSpero Therapeutics2026-07-27 13:00 EST
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Stock data
- Close
- 1.22 USD
- Market cap
- 163.86M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States